Ipsen acquires Syntaxin of the UK

The French specialty pharmaceutical company Ipsen SA has reached an agreement to acquire Syntaxin Ltd of the UK in a deal potentially valued at €158 million, while simultaneously announcing an agreement in neurology with Harvard Medical School.